Sector News

Gilead secures access to NASH drug in $1.2-bn deal

April 5, 2016
Life sciences

Gilead Sciences is snapping up a subsidiary of Nimbus Therapeutics for access to its experimental therapy for a metabolic disorder causing fat buildup in the liver.

The firm is prepared to shell out $1.2 billion under the deal; $400 million for Nimbus Apollo and a further $800 million to parent company Nimbus Therapeutics if certain developmental, regulatory and sales milestones are met.

The Nimbus Apollo programme includes lead candidate NDI-010976, an ACC inhibitor, and other preclinical ACC inhibitors for the treatment of non-alcoholic steatohepatitis (NASH), and for the potential treatment of hepatocellular carcinoma (HCC) and other diseases.

NDI-010976 was granted Fast Track designation by the US Food and Drug Administration in February; Phase I data for the compound are to be presented next month during at The International Liver Congress 2016, the annual meeting of the European Association for the Study of the Liver (EASL).

NASH is a serious liver disease resulting from metabolic dysfunction that causes toxic build-up of fat in the liver (steatosis) that can lead to inflammation, hepatocellular injury, progressive fibrosis and cirrhosis. The condition currently affects up to 15 million people in the US and, as Gilead notes, is expected to become the leading indication for liver transplantation by 2020.

“The acquisition of Nimbus’ ACC-inhibitor program represents a timely and important opportunity to accelerate Gilead’s ongoing efforts to address unmet needs in NASH,” said Norbert Bischofberger, Gilead’s chief scientific officer. “These molecules will complement and further strengthen Gilead’s pipeline and capabilities to advance a broad clinical program in NASH that includes compounds targeting multiple key pathways involved in the pathogenesis of the disease.”

By Selina McKee

Source: Pharma Times

Related News

March 6, 2021

Takeda takes full control of drug for rare epilepsies

Life sciences

The deal inked with New York-based Ovid Therapeutics carries an almost $200 million upfront payment and could be worth as much as $856 million provided the medicine, known as soticlestat, hits certain milestones. 

March 6, 2021

Novartis signs Covid-19 vaccine manufacturing agreement with CureVac

Life sciences

Novartis has entered an initial agreement to manufacture the mRNA and bulk drug product for CureVac’s Covid-19 vaccine candidate, CVnCoV.

March 6, 2021

Disney teams with Philips to bring its characters to pediatric imaging

Life sciences

A whole new world: Philips and the Walt Disney Company will use animated shorts featuring some of Disney’s most famous characters in customized stories created with clinical guidance from Philips.

Send this to a friend